Report Detail

Request for Sample of this report

Pharma & Healthcare Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

  • RnM4588625
    • |
  • 21 May, 2024
    • |
  • Global
    • |
  • 90 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Pharma & Healthcare

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent refers to an inactivated split influenza vaccine whose vaccine components include A (H3N2) subtype, A (H1N1) pdm09 subtype, and type B Victoria and Yamagata lines.
According to our (Global Info Research) latest study, the global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Hualan Bacterin, Sinovac Biotech, Sanofi, CSL Seqirus, GSK, Adimmune, Sinopharm, Jiangsu GDK Biotechnology, Abbott, Ab&B BIO-TECH, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Child
Adult
Elder
Market segment by Application
Hospital
Clinic
Major players covered
Hualan Bacterin
Sinovac Biotech
Sanofi
CSL Seqirus
GSK
Adimmune
Sinopharm
Jiangsu GDK Biotechnology
Abbott
Ab&B BIO-TECH
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, with price, sales quantity, revenue, and global market share of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent from 2019 to 2024.
Chapter 3, the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent.
Chapter 14 and 15, to describe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Child
    • 1.3.3 Adult
    • 1.3.4 Elder
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Hospital
    • 1.4.3 Clinic
  • 1.5 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size & Forecast
    • 1.5.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019 & 2023 & 2030)
    • 1.5.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (2019-2030)
    • 1.5.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price (2019-2030)

2 Manufacturers Profiles

  • 2.1 Hualan Bacterin
    • 2.1.1 Hualan Bacterin Details
    • 2.1.2 Hualan Bacterin Major Business
    • 2.1.3 Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
    • 2.1.4 Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Hualan Bacterin Recent Developments/Updates
  • 2.2 Sinovac Biotech
    • 2.2.1 Sinovac Biotech Details
    • 2.2.2 Sinovac Biotech Major Business
    • 2.2.3 Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
    • 2.2.4 Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Sinovac Biotech Recent Developments/Updates
  • 2.3 Sanofi
    • 2.3.1 Sanofi Details
    • 2.3.2 Sanofi Major Business
    • 2.3.3 Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
    • 2.3.4 Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Sanofi Recent Developments/Updates
  • 2.4 CSL Seqirus
    • 2.4.1 CSL Seqirus Details
    • 2.4.2 CSL Seqirus Major Business
    • 2.4.3 CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
    • 2.4.4 CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 CSL Seqirus Recent Developments/Updates
  • 2.5 GSK
    • 2.5.1 GSK Details
    • 2.5.2 GSK Major Business
    • 2.5.3 GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
    • 2.5.4 GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 GSK Recent Developments/Updates
  • 2.6 Adimmune
    • 2.6.1 Adimmune Details
    • 2.6.2 Adimmune Major Business
    • 2.6.3 Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
    • 2.6.4 Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Adimmune Recent Developments/Updates
  • 2.7 Sinopharm
    • 2.7.1 Sinopharm Details
    • 2.7.2 Sinopharm Major Business
    • 2.7.3 Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
    • 2.7.4 Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 Sinopharm Recent Developments/Updates
  • 2.8 Jiangsu GDK Biotechnology
    • 2.8.1 Jiangsu GDK Biotechnology Details
    • 2.8.2 Jiangsu GDK Biotechnology Major Business
    • 2.8.3 Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
    • 2.8.4 Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 Jiangsu GDK Biotechnology Recent Developments/Updates
  • 2.9 Abbott
    • 2.9.1 Abbott Details
    • 2.9.2 Abbott Major Business
    • 2.9.3 Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
    • 2.9.4 Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.9.5 Abbott Recent Developments/Updates
  • 2.10 Ab&B BIO-TECH
    • 2.10.1 Ab&B BIO-TECH Details
    • 2.10.2 Ab&B BIO-TECH Major Business
    • 2.10.3 Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
    • 2.10.4 Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.10.5 Ab&B BIO-TECH Recent Developments/Updates

3 Competitive Environment: Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Manufacturer

  • 3.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Manufacturer (2019-2024)
  • 3.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Manufacturer (2019-2024)
  • 3.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Manufacturer (2019-2024)
  • 3.4 Market Share Analysis (2023)
    • 3.4.1 Producer Shipments of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Manufacturer Revenue ($MM) and Market Share (%): 2023
    • 3.4.2 Top 3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturer Market Share in 2023
    • 3.4.3 Top 6 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturer Market Share in 2023
  • 3.5 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Overall Company Footprint Analysis
    • 3.5.1 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Region Footprint
    • 3.5.2 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Company Product Type Footprint
    • 3.5.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Region
    • 4.1.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Region (2019-2030)
    • 4.1.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Region (2019-2030)
    • 4.1.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Region (2019-2030)
  • 4.2 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030)
  • 4.3 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030)
  • 4.4 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030)
  • 4.5 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030)
  • 4.6 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030)

5 Market Segment by Type

  • 5.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
  • 5.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Type (2019-2030)
  • 5.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Type (2019-2030)

6 Market Segment by Application

  • 6.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
  • 6.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Application (2019-2030)
  • 6.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Application (2019-2030)

7 North America

  • 7.1 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
  • 7.2 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
  • 7.3 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country
    • 7.3.1 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2030)
    • 7.3.2 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2030)
    • 7.3.3 United States Market Size and Forecast (2019-2030)
    • 7.3.4 Canada Market Size and Forecast (2019-2030)
    • 7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe

  • 8.1 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
  • 8.2 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
  • 8.3 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country
    • 8.3.1 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2030)
    • 8.3.2 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2030)
    • 8.3.3 Germany Market Size and Forecast (2019-2030)
    • 8.3.4 France Market Size and Forecast (2019-2030)
    • 8.3.5 United Kingdom Market Size and Forecast (2019-2030)
    • 8.3.6 Russia Market Size and Forecast (2019-2030)
    • 8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific

  • 9.1 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
  • 9.2 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
  • 9.3 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Region
    • 9.3.1 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Region (2019-2030)
    • 9.3.2 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Region (2019-2030)
    • 9.3.3 China Market Size and Forecast (2019-2030)
    • 9.3.4 Japan Market Size and Forecast (2019-2030)
    • 9.3.5 South Korea Market Size and Forecast (2019-2030)
    • 9.3.6 India Market Size and Forecast (2019-2030)
    • 9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
    • 9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America

  • 10.1 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
  • 10.2 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
  • 10.3 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country
    • 10.3.1 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2030)
    • 10.3.2 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2030)
    • 10.3.3 Brazil Market Size and Forecast (2019-2030)
    • 10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa

  • 11.1 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
  • 11.2 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
  • 11.3 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country
    • 11.3.1 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2030)
    • 11.3.2 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2030)
    • 11.3.3 Turkey Market Size and Forecast (2019-2030)
    • 11.3.4 Egypt Market Size and Forecast (2019-2030)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
    • 11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics

  • 12.1 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Drivers
  • 12.2 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Restraints
  • 12.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
  • 13.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Typical Distributors
  • 14.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Influenza Vaccine (Split Virion), Inactivated, Quadrivalent. Industry analysis & Market Report on Influenza Vaccine (Split Virion), Inactivated, Quadrivalent is a syndicated market report, published as Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,742.24
    		4,113.36
    		5,484.48
    		3,250.32
    		4,875.48
    		6,500.64
    		547,682.40
    		821,523.60
    		1,095,364.80
    		290,823.60
    		436,235.40
    		581,647.20
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo